2009
DOI: 10.5465/amj.2009.43670897
|View full text |Cite
|
Sign up to set email alerts
|

The Dynamics of Multimarket Competition in Exploration and Exploitation Activities

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

6
97
0

Year Published

2010
2010
2022
2022

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 95 publications
(103 citation statements)
references
References 68 publications
6
97
0
Order By: Relevance
“…After consulting researchers in the academic areas related to clinical trials, we conclude that market exploration orientation can be measured as changes in the therapy codes utilised by the firm. This point is further confirmed by the research conducted by Anand, Mesquita, and Vassolo (2009), where the authors interviewed industry executives, pharmacists, hospital doctors and clinicians before they concluded that 'each market represents, and is named after, a therapeutic treatment' (807) and, hence, a market referred to a therapeutic class. This raises the validity of this indicator of therapy code as market exploration orientation in this study.…”
Section: Methodsmentioning
confidence: 63%
“…After consulting researchers in the academic areas related to clinical trials, we conclude that market exploration orientation can be measured as changes in the therapy codes utilised by the firm. This point is further confirmed by the research conducted by Anand, Mesquita, and Vassolo (2009), where the authors interviewed industry executives, pharmacists, hospital doctors and clinicians before they concluded that 'each market represents, and is named after, a therapeutic treatment' (807) and, hence, a market referred to a therapeutic class. This raises the validity of this indicator of therapy code as market exploration orientation in this study.…”
Section: Methodsmentioning
confidence: 63%
“…Specifically, alliances that focus on discovery and development of new technology (such as R&D alliances) are coded as exploration alliances (Anand, Mesquita, & Vassolo, 2009), and other alliances that focus on marketing and resource utilization (such as licensing, marketing, and other supplying alliances) are treated as exploitation alliances. In some special cases where an alliance was created for both exploration and exploitation, we assign a weight of 0.5 to the coding.…”
Section: Independent Variablesmentioning
confidence: 99%
“…In our study, clear market definitions are important because firms defined to be a pharmaceutical firm's rivals should be actual, meaningful competitors whose products are substitutes for those of the pharmaceutical firm. Defining markets by therapeutic classes is widely-accepted and commonly-used by U.S. government authorities, industry players, and academic researchers (Anand, Mesquita, & Vassolo, 2009;Lerner, 1997;Rothaermel, 2001;Vassolo, Anand, & Folta, 2004).…”
Section: Data and Samplementioning
confidence: 99%
“…We matched the first level of the ATC Classification System (e.g., cardiovascular system, dermatologicals) to the therapeutic class of the R&D alliance as reported by Recap to determine whether the sales were in the product market corresponding to therapeutic area of the R&D alliance (Anand et al, 2009). Based on this information, we measured the independent variable, Risk from Partner-Rival Co-location, by calculating the weighted average of the aggregate market shares held by the nearby rivals in the focal product markets (i.e., therapeutic classes) of the R&D alliance.…”
mentioning
confidence: 99%